MAGNEVIST

LOE Approaching

gadopentetate dimeglumine

NDAINJECTIONINJECTABLEPriority Review
Approved
Jun 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14

Clinical Trials (5)

NCT01050829Phase 3Completed

Gadobutrol Magnevist-controlled Body Study

Started Jan 2010
370 enrolled
Magnetic Resonance Imaging
NCT00744939N/ACompleted

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

Started Nov 2008
168 enrolled
FibrosisKidney FailureRenal Insufficiency
NCT01376739N/ACompleted

Magnevist Post-marketing Surveillance in Japan

Started Aug 2007
2,051 enrolled
Diagnostic Imaging
NCT00486473Phase 3Completed

Multihance Versus Magnevist in Breast MRI

Started Jul 2007
130 enrolled
Breast Cancer
NCT00395733Phase 3Completed

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients

Started Oct 2006
83 enrolled
Vascular Diseases